Immutep reports 81.1% 12-month disease-free survival in the EFTISARC-NEO Phase II trial evaluating eftilagimod alfa with pembrolizumab and radiotherapy in resectable soft tissue sarcoma.
Written By: Faiza, PharmD
Reviewed By: Pharmacally Editorial Team
Immutep Limited reported encouraging survival findings from its investigator-initiated EFTISARC-NEO Phase II trial (NCT06128863), showing a Kaplan-Meier estimated disease-free survival (DFS) rate of 81.1% at 12 months in patients with high-risk, resectable soft tissue sarcoma (STS). The findings were presented at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting (Poster P448) on November 19, 2026.
The study evaluates eftilagimod alfa (efti), Immutep’s proprietary soluble LAG-3 protein and MHC Class II agonist, with KEYTRUDA® (pembrolizumab) and radiotherapy before surgery. Efti activates antigen-presenting cells to stimulate innate and adaptive immunity, including cytotoxic CD8+ T-cell priming.
Trial Design and Participant Characteristics
EFTISARC-NEO is an open-label, investigator-initiated Phase II trial led by the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland. The Polish Medical Research Agency primarily funds the study, while Immutep supplies efti.
The trial enrolled 40 patients, completing recruitment in January 2025. Of these, 38 underwent surgery and entered the survival evaluation. The latest analysis had a data cut-off of April 30, 2026, with a median follow-up of 19.1 months.
Treatment comprised efti 30 mg subcutaneously every two weeks for five doses, pembrolizumab 200 mg intravenously every three weeks for three doses, and radiotherapy at 50 Gy over five weeks, followed by surgery.
Primary Endpoint: Pathological Response
The trial previously met its primary endpoint, measuring tumour hyalinisation and fibrosis at surgical resection. Among 38 evaluable patients, median hyalinisation and fibrosis reached 51.5% (interquartile range, 15%–76%), exceeding the prespecified 35% target. This compared with approximately 15% historically observed with radiotherapy alone, with the previously reported analysis demonstrating statistical significance (p less than 0.001). The historical comparison was not based on a randomized control group.
Secondary Endpoint: Survival Outcomes
The latest analysis showed 81.1% DFS at 12 months, described as mature. The 18-month Kaplan-Meier estimate was also 81.1%, although it remains immature. Eight of the 38 evaluated patients had experienced recurrence by the data cut-off, and follow-up for overall survival remains ongoing.
Other 12-month outcomes included:
- Local recurrence-free survival: 94.1%
- Distant metastasis-free survival: 86.2%
The earlier analysis reported no differences in DFS across tumour grade, disease stage, or histological subtype.
Exploratory Biomarker Findings
Exploratory analyses associated higher tumour-infiltrating lymphocyte (TIL) levels and greater treatment-related hyalinisation and fibrosis with improved DFS.
Patients with post-treatment TIL levels above 310 cells/mm² had 95.0% 12-month DFS, compared with 64.9% among those with lower levels. Patients with hyalinisation and fibrosis above 52% had 93.8% DFS, compared with 71.4%.
Tertiary lymphoid structures and baseline PD-L1, LAG-3, and TIGIT expression did not correlate with survival. These subgroup findings are hypothesis-generating and do not establish validated predictive biomarkers or independent treatment effects. Detailed statistical parameters were not disclosed.
Safety Findings
Previously reported results showed treatment-related adverse events in 92.5% of patients (37/40), including Grade 3 or 4 events in 20.0% (8/40). Two patients discontinued treatment because of treatment-related adverse events, and all patients who underwent resection proceeded to intended surgery without treatment-related delay. These findings were not updated in the November 19 announcement.
Separately, ESMO 2026 quality-of-life data showed no significant deterioration during neoadjuvant treatment. The QLQ-C30 summary score improved by 6.0 points following surgery (p = 0.008).
Regulatory Status
Efti has received FDA Fast Track designation in first-line head and neck squamous cell carcinoma and first-line non-small cell lung cancer, alongside Orphan Drug Designation for STS in April 2026.
Immutep expects additional EFTISARC-NEO data in CY2027 and is preparing a registration-directed neoadjuvant STS trial, targeting initiation in H2 CY2027. The timeline remains subject to regulatory discussions, manufacturing, partnering arrangements, and available resources.
Clinical Interpretation and Limitations
The 81.1% 12-month DFS finding extends EFTISARC-NEO’s evidence beyond its previously reported pathological response results. The exploratory biomarker associations also provide potential directions for investigating immune response markers in neoadjuvant STS treatment.
However, only 38 patients were evaluated for survival, and the single-arm study lacks a randomized comparator to establish the incremental benefit of adding efti and pembrolizumab to radiotherapy and surgery. The 18-month DFS estimate remains immature, while exploratory biomarker findings cannot establish causality or independent prognostic value. Larger randomized studies and longer follow-up will be necessary to determine whether these findings translate into clinically meaningful improvements.
Reference
Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma, Immutep, 19 November 2026
Pembrolizumab in Combination with Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients with Soft Tissue Sarcoma – EFTISARC-NEO Trial (EFTISARC-NEO), ClinicalTrials.gov ID NCT06128863
About the Writer
Faiza (Linkedin) is a Healthcare Writer at Pharmacally and a PharmD professional from St. Peter’s Institute of Pharmaceutical Sciences, Kakatiya University. she has academic and clinical interests in clinical pharmacy, pharmacovigilance and patient care. Her research focuses on serum biomarkers in acute pancreatitis and medication adherence. She is interested in clinical research, medical writing and evidence-based healthcare communication.
